Form 4: Daxor Corp Director Granted Stock Options

Daxor Corp Director Henry Cremisi was granted stock options contingent on SEC approval of an amended incentive plan.

Summary

• Henry D. Cremisi, a Director at Daxor Corp (DXR), was granted 2,500 stock options with an exercise price of $10.14.
• The grant is contingent upon the SEC's approval to amend the Daxor Corporation 2020 Incentive Compensation Plan.
• The stock options are set to vest in three installments: 833 on June 23, 2026, 883 on June 23, 2027, and 834 on June 23, 2028.
• The options have an expiration date of June 23, 2031.
• This filing is made pursuant to Section 16(a) of the Securities Exchange Act of 1934.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details a standard compensation practice for a director, but the outcome is contingent on regulatory approval, introducing uncertainty.

Positives

• Director granted stock options, indicating potential alignment of management interests with shareholder value.
• The grant of options suggests management's belief in the future growth and value of Daxor Corp.

Negatives

• The grant is contingent on SEC approval, introducing an element of uncertainty.
• The exercise price of $10.14 implies that the stock price needs to increase significantly for the options to be profitable.

Risks

• The primary risk is the potential disapproval of the amended incentive compensation plan by the SEC, which would invalidate the stock option grant.
• Future stock price performance of Daxor Corp (DXR) is a risk, as the options will only be valuable if the stock price exceeds the exercise price of $10.14.

Future Outlook

The future outlook for the stock options is dependent on SEC approval of the amended incentive plan and the future performance of Daxor Corp's stock price, which must exceed $10.14 for the options to be in-the-money.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and healthcare sectors, aiming to incentivize long-term performance and align executive interests with shareholders. However, the reliance on SEC approval for the incentive plan's amendment is a specific procedural hurdle.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options could dilute ownership if exercised, but also aligns director incentives with stock appreciation.
• Employees: The incentive plan amendment, if approved, could set a precedent for future employee compensation structures.
• Management: Direct benefit through potential stock option gains.

Next Steps

• Await SEC approval for the amendment to the Daxor Corporation 2020 Incentive Compensation Plan.
• Monitor Daxor Corp's stock performance relative to the $10.14 exercise price of the granted options.

Key Dates

Keywords

Daxor Corp, DXR, Form 4, Stock Options, SEC Filing, Director Compensation, Incentive Plan, Beneficial Ownership, Insider Trading